Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis.
Journal: Muscle & nerve
Published: April 22, 2024
Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world.
Journal: Expert opinion on drug safety
Published: June 05, 2023
Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: April 21, 2022
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Journal: The Lancet. Neurology
Published: November 03, 2021
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Journal: CNS drugs
Published: March 10, 2021
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
Journal: Journal of medicinal chemistry
Published: July 23, 2020
The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: August 30, 2019
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Journal: Neurology
Published: October 25, 2018
Risk of pure red cell aplasia in patients with hepatitis C receiving antiviral therapy and an erythropoiesis-stimulating agent.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: January 28, 2013
Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.
Journal: Journal of the American College of Cardiology
Published: May 22, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026